Research Highlights

ImmunoLin Improves Quality of Life
Researchers from Proliant Health and Biologicals have observed that symptoms in digestive disorders—typically abdominal cramps and diarrhea—signal inflammation, and are common in immune deficiencies. In a new study using ImmunoLin—an immunoglobulin protein isolate with immune-enhancing effects, developed by Proliant—company researchers successfully improved quality-of-life and reduced symptoms of Irritable Bowel Syndrome (IBS). Leading up to the IBS study, Proliant researchers observed that inducing mild inflammation produces changes in gut permeability, a factor in IBS. As permeability increases, more antigens (toxins) enter the gut, triggering the immune reaction and inflammation that cause the pain and diarrhea associated with IBS. The researchers surmised that if they could eliminate foreign antigens—a core function of ImmunoLin—symptoms of IBS would subside.
Researchers recruited 33 females and 18 males—the disorder is more prevalent in women—aged 40 to 55 with diarrhea-predominant IBS. During the six-week double-blind study, subjects randomly received one of three treatments: 10 grams of ImmunoLin, 10 grams of soy protein, or a combination of 5 grams of ImmunoLin and 5 grams of soy protein, in 20 capsules per day, taken five at a time. Overall days with symptoms decreased by 16% and 18% in the 5 gram ImmunoLin and 10 gram ImmunoLin groups, respectively, compared to the soy protein control group. From week four through week six, overall days with symptoms decreased by 24% in the 10 gram ImmunoLin group compared to the soy control group.
For further information: 515-289-7621.

New Study to Evaluate Celadrin Capsules for Patients with Knee Pain
Imagenetix has initiated a new multi-site study on Celadrin, a natural ingredient for joint health. Patients currently diagnosed with moderate-to-severe knee pain are now being enrolled in the study, which is expected to be complete later this year. Patients will consume Celadrin or placebo in capsule form throughout the 60-day, double-blind, placebo-controlled trial.
Dr. Jay Udani, MD, medical director of Medicus Research, a private clinical trials facility located in Northridge, CA, will serve as the project manager and principal investigator. Patients will be enrolled at two locations—Northridge, CA, and Ellicot City, MD. Apart from his role at Medicus Research, Dr. Udani is also